Factor | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
p value | p value | Estimate | Lower 95 % CI | Upper 95 % CI | ||
Country of origin | Middle East vs. Asia vs. Africa vs. Europe or U.S.A. | 0.17 | ||||
Age at diagnosis (years) | ≤median vs. >median | 0.61 | ||||
Volume of the PTV (cm3) | ≤median vs. >median | 0.01 | 0.0002 | 1.52 | 0.72 | 2.32 |
BMI | <25 vs. 25.0–29.9 vs. 30.0–34.9 vs. 35.0–39.9 vs. ≥40.0 | 0.03 | ||||
Menopausal status | Pre- vs. post-menopausal | 0.56 | ||||
T classification | Tis, T0,T1,T2 vs. T3,T4 | 0.51 | ||||
N classification | N0 vs. N1, N2, N3 | 0.28 | ||||
Grading | G1, G2 vs. G3 | 0.61 | ||||
ER status | Negative vs. positive | 0.98 | ||||
PR status | Negative vs. positive | 0.79 | ||||
Her2/neu status | Negative vs. positive | 0.38 | ||||
Fractionation regimen | CF vs. HF | <0.0001 | <0.00001 | 2.14 | 1.32 | 3.33 |
Planning Target Volume (PTV) | Breast vs. chest wall | 0.02 | ||||
Locoregional lymph nodes treated as part of plan | Yes vs. no | 0.76 | ||||
Radiation technique | 3DCRT vs. TB-IMRT | 0.42 | ||||
Chemotherapy | Neoadjuvant vs. adjuvant vs. no chemotherapy | 0.22 | ||||
Hormonal therapy | Yes vs. no | 0.60 |